Clinical Trial VICCPHI1327


A Phase 1, Open-Label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Principal Investigator(s)

Jordan Berlin


  • Protocol No. VICCPHI1327
  • Open Date: 07/29/2013
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the safety, tolerability, and MTD of OPB-111077 administered orally QD for 4 weeks (28 days) to subjects with advanced cancer.
  • Disease Sites: Phase I
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: OPB-111077
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01711034
  • Secondary Protocol No: 317-11-201



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.